Passage Bio (PASG) Stock Forecast, Price Target & Predictions
PASG Stock Forecast
Passage Bio stock forecast is as follows: an average price target of $6.00 (represents a 752.27% upside from PASG’s last price of $0.70) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
PASG Price Target
The average price target for Passage Bio (PASG) is $6.00 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $6.00 to $6.00. This represents a potential 752.27% upside from PASG's last price of $0.70.
PASG Analyst Ratings
According to 5 Wall Street analysts, Passage Bio's rating consensus is 'Buy'. The analyst rating breakdown for PASG stock is 0 'Strong Buy' (0.00%), 4 'Buy' (80.00%), 1 'Hold' (20.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Passage Bio Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jan 19, 2022 | Madhu Kumar | Goldman Sachs | $6.00 | $4.94 | 21.46% | 752.27% |
The latest Passage Bio stock forecast, released on Jan 19, 2022 by Madhu Kumar from Goldman Sachs, set a price target of $6.00, which represents a 21.46% increase from the stock price at the time of the forecast ($4.94), and a 752.27% increase from PASG last price ($0.70).
Passage Bio Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | - | - |
| Avg Price Target | - | - | - |
| Last Closing Price | $0.70 | $0.70 | $0.70 |
| Upside/Downside | -100.00% | -100.00% | -100.00% |
In the current month, the average price target of Passage Bio stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Passage Bio's last price of $0.70. This month's average price target is down NaN% compared to last quarter, and down NaN% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Sep 03, 2024 | Rodman & Renshaw | - | Buy | Initialise |
| Nov 14, 2023 | Raymond James | Outperform | Outperform | Hold |
| Dec 15, 2022 | Chardan Capital | Buy | Buy | Hold |
| Nov 11, 2022 | Guggenheim | Buy | Buy | Hold |
| May 17, 2022 | Raymond James | Outperform | Outperform | Hold |
| Jan 19, 2022 | Goldman Sachs | - | Neutral | Downgrade |
Passage Bio's last stock rating was published by Rodman & Renshaw on Sep 03, 2024. The company Initialise its PASG rating from "null" to "Buy".
Passage Bio Financial Forecast
Passage Bio Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | $2.00M | - |
| High Forecast | - | - | - | - | - | $2.00M | - |
| Low Forecast | - | - | - | - | - | $2.00M | - |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 |
| Surprise % | - | - | - | - | - | - | - |
Passage Bio's average Quarter revenue forecast for undefined based on undefined analysts is $NaN, with a low forecast of $NaN, and a high forecast of $NaN. PASG's average Quarter revenue forecast represents a NaN% decrease compared to the company's last Quarter revenue of $NaN (undefined).
Passage Bio EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 |
| EBITDA | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
undefined analysts predict PASG's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than Passage Bio's previous annual EBITDA (undefined) of $NaN.
Passage Bio Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 |
| Net Income | - | - | - | - | - | - | - |
| Avg Forecast | $-10.02M | $-9.89M | $-11.29M | $-11.15M | $-12.70M | $-14.57M | $-19.07M |
| High Forecast | $-10.02M | $-9.89M | $-11.29M | $-11.15M | $-12.70M | $-10.77M | $-19.07M |
| Low Forecast | $-10.02M | $-9.89M | $-11.29M | $-11.15M | $-12.70M | $-17.73M | $-19.07M |
| Surprise % | - | - | - | - | - | - | - |
Passage Bio's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. PASG's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Passage Bio SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 |
| SG&A | - | - | - | - | - | - | - |
| Avg Forecast | - | - | - | - | - | - | - |
| High Forecast | - | - | - | - | - | - | - |
| Low Forecast | - | - | - | - | - | - | - |
| Surprise % | - | - | - | - | - | - | - |
Passage Bio's average Quarter SG&A projection for undefined is $NaN, based on undefined Wall Street analysts, with a range of $NaN to $NaN. The forecast indicates a NaN% fall compared to PASG last annual SG&A of $NaN (undefined).
Passage Bio EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | |
|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 |
| EPS | - | - | - | - | - | - | - |
| Avg Forecast | $-0.16 | $-0.16 | $-0.18 | $-0.18 | $-0.21 | $-0.24 | $-0.31 |
| High Forecast | $-0.16 | $-0.16 | $-0.18 | $-0.18 | $-0.21 | $-0.17 | $-0.31 |
| Low Forecast | $-0.16 | $-0.16 | $-0.18 | $-0.18 | $-0.21 | $-0.29 | $-0.31 |
| Surprise % | - | - | - | - | - | - | - |
According to undefined Wall Street analysts, Passage Bio's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to PASG previous annual EPS of $NaN (undefined).
Passage Bio Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| PASG | Passage Bio | $0.70 | $6.00 | 757.14% | Buy |
| CABA | Cabaletta Bio | $4.26 | $16.33 | 283.33% | Buy |
| FIXX | Q32 Bio | $0.93 | $2.70 | 190.32% | Buy |
| BDTX | Black Diamond Therapeutics | $5.40 | $14.75 | 173.15% | Buy |
| STOK | Stoke Therapeutics | $14.70 | $33.33 | 126.73% | Buy |
| RVMD | Revolution Medicines, Inc. Warrant | $41.84 | $51.20 | 22.37% | Buy |
PASG Forecast FAQ
Is Passage Bio a good buy?
Yes, according to 5 Wall Street analysts, Passage Bio (PASG) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 4 'Buy' recommendations, accounting for 80.00% of PASG's total ratings.
What is PASG's price target?
Passage Bio (PASG) average price target is $6 with a range of $6 to $6, implying a 752.27% from its last price of $0.704. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Passage Bio stock go up soon?
According to Wall Street analysts' prediction for PASG stock, the company can go up by 752.27% (from the last price of $0.704 to the average price target of $6), up by 752.27% based on the highest stock price target, and up by 752.27% based on the lowest stock price target.
Can Passage Bio stock reach $1?
PASG's average twelve months analyst stock price target of $6 supports the claim that Passage Bio can reach $1 in the near future.
What are Passage Bio's analysts' financial forecasts?
Passage Bio's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $2M (high $2M, low $2M), average EBITDA is $0 (high $0, low $0), average net income is $-46.345M (high $-42.544M, low $-49.511M), average SG&A $0 (high $0, low $0), and average EPS is $-0.751 (high $-0.69, low $-0.803). PASG's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $0 (high $0, low $0), average EBITDA is $0 (high $0, low $0), average net income is $-42.351M (high $-42.351M, low $-42.351M), average SG&A $0 (high $0, low $0), and average EPS is $-0.687 (high $-0.687, low $-0.687).